Principal Scientist/Sr. Principal Scientist - Bioconjugation Process Development at Eli Lilly and Company

Indianapolis, Indiana, United States

Apply Now

Not SpecifiedCompensation

Senior (5 to 8 years), Expert & Leadership (9+ years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, PharmaceuticalsIndustries

Requirements

BS with 6+ years of relevant experience or Master’s degree with 3+ years of relevant experience in synthetic organic chemistry, biochemistry, chemical biology, chemical engineering or related field
Experience with synthetic organic chemistry or biochemistry
Drive to learn about bioconjugation principles to produce ADCs and similar modalities
Additional Skills/Preferences
Experience with small molecule organic synthesis, knowledge of reaction mechanisms, and design of reactions
Experience with performing bioconjugation reactions at small-scale
Knowledge of basic antibody class, structure

Responsibilities

Establish a productive laboratory program by directly designing and executing internal research plans, collaborate with teammates to analyze the results, form conclusions, propose logical next steps, and report findings to a larger team
Learn and apply new skills such as bioconjugation, purification screening, OFAT and Design of Experiment methodology, and analytical sample analysis
Operate at the interface between disciplines and departments to quickly move from one scientific challenge to another while navigating ambiguity
Perform fundamental and detailed studies of each process step for bioconjugation development
Perform scale-up demonstrations of bioconjugation processes and purifications to provide material and information for development purposes
Propose and test new methods to achieve bioconjugation and bioconjugate development. Collaborate and share findings with partners
Demonstrate strong oral and written communication skills
Perform necessary documentation work such as electronic notebook maintenance, report authoring and regulatory/manufacturing documentation
Bring new and useful concepts, methods, and ideas for how research can be improved and share these to make our group better
Demonstrate learning agility across modalities (e.g. small molecule, peptide and oligonucleotide)
Help formulate commercial manufacturing strategy and collaborate with manufacturing partners to deliver robust processes that are ultimately suitable for large-scale production

Skills

bioconjugation

synthetic organic chemistry

biochemistry

ADC process development

antibody-drug conjugates

antibody-peptide conjugates

antibody-RNA conjugates

process development

biologic therapeutics

mAbs

Eli Lilly and Company

Develops and delivers prescription medicines globally

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that focuses on discovering, developing, and delivering medicines to improve health. The company has a long history of scientific achievements, including the creation of insulin, the first life-saving treatment for diabetes. Lilly's operations involve extensive research and development to create new medications and enhance existing ones, ensuring they are safe and effective. Their products are primarily prescription medicines sold to healthcare providers for various medical conditions, including diabetes, cancer, and pain management. What sets Lilly apart from its competitors is its strong commitment to ethical practices and the protection of its products from counterfeiting. The company's goal is to enhance lives through innovative medical solutions while maintaining high standards of quality and ethics.

Indianapolis, IndianaHeadquarters

1876Year Founded

$1,180.1MTotal Funding

IPOCompany Stage

Biotechnology, HealthcareIndustries

10,001+Employees

Risks

Competition from Novo Nordisk's Ozempic may impact tirzepatide's market share.

Potential construction delays in Indiana could affect GLP-1 drug production timelines.

Regulatory challenges may hinder Kisunla's expansion in new Alzheimer's markets.

Differentiation

Eli Lilly's rich history includes the first life-saving insulin treatment.

Lilly's strategic partnerships enhance its position in neurodegenerative disease treatments.

FDA approval of Zepbound opens new therapeutic markets for sleep disorder treatments.

Upsides

Lilly's $9 billion complex in Indiana boosts GLP-1 drug production capacity.

Kisunla's approval in China expands Lilly's Alzheimer's treatment market in Asia.

Collaboration with EVA Pharma enhances Lilly's reputation as socially responsible.

Land your dream remote job 3x faster with AI

Try Jobo Free